<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153227</url>
  </required_header>
  <id_info>
    <org_study_id>CEIm 2019/643</org_study_id>
    <nct_id>NCT04153227</nct_id>
  </id_info>
  <brief_title>Osteoporosis, Trabecular Bone Score and Fracture Risk Assessment in Male Patients After Radical Cystectomy</brief_title>
  <official_title>Impact on Bone Health in Patients Undergoing Radical Cystectomy: Prevalence of Osteoporosis, Trabecular Bone Score (TBS) Assessment and Fracture Risk by FRAX in Male Patients After One Year of Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical cystectomy is associated with a greater risk of fracture due to long-term metabolic&#xD;
      consequences of intestinal urinary diversions. One of the mechanisms theoretically involved&#xD;
      with bone loss after radical cystectomy is metabolic acidosis that inhibits osteoblast&#xD;
      activity, stimulates osteoclast bone resorption and urinary calcium loss. Other factors as&#xD;
      advanced age, diabetes or chronic renal failure may increase the effect of metabolic&#xD;
      acidosis. Moreover, osteoporosis in men remains under-diagnosed and under-appreciated.&#xD;
&#xD;
      Although metabolic and bone changes after radical cystectomy are well known, bone mineral&#xD;
      density (BMD) or fracture risk assessment are not recommended in different international&#xD;
      guidelines during follow-up.&#xD;
&#xD;
      The objective of this study is to evaluate the fracture risk of male patients undergoing&#xD;
      radical cystectomy after more than one year of follow-up. Fracture risk assessment will be&#xD;
      performed by BMD to analyse the prevalence of osteoporosis, vertebral fractures and&#xD;
      measurement of Trabecular Bone Score (TBS) in combination with the Fracture Risk Assessment&#xD;
      Tool (FRAX). These results will be correlated with blood markers with the objective to&#xD;
      determine independent risk factors for osteoporosis or bone fracture in this population.&#xD;
&#xD;
      To the best of the investigator's knowledge this will be the first study assessing the&#xD;
      fracture risk after radical cystectomy performance evaluating BMD and the probability of&#xD;
      fracture at 10 years using the FRAX algorithm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Number of patients with osteoporosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone score</measure>
    <time_frame>Baseline</time_frame>
    <description>Trabecular bone score (TBS) is a lumbar spine dual-energy absorptiometry texture index, which provides information on microarchitecture skeletal quality partially independent of BMD (TBS values &gt;1.310 normal; TBS: 1.310-1.230 microarchitecture partially degraded; TBS &lt;1.230 microarchitecture degraded).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertebral fractures</measure>
    <time_frame>Baseline</time_frame>
    <description>Presence of vertebral fractures evaluated by Vertebral Fracture Assessment (VFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FRAX Assessment Tool</measure>
    <time_frame>Baseline</time_frame>
    <description>FRAX provides country-specific algorithms for estimating individualized 10-year probability of hip and major osteoporotic fracture (FRAX with and without BMD and FRAX with TBS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with metabolic acidosis.</measure>
    <time_frame>Baseline</time_frame>
    <description>Metabolic acidosis is considered if venous serum bicarbonate &lt;23mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with Secondary hyperparathyroidism.</measure>
    <time_frame>Baseline</time_frame>
    <description>Secondary hiperparathyroidism is considered if Serum parathyroid hormone (PTH) &gt;65 pg/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with Serum total 25(OH) vitamin D deficiency.</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum total 25(OH) vitamine D deficiency is considered if &lt;30 ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with moderate-severe chronic kidney disease</measure>
    <time_frame>Baseline</time_frame>
    <description>Glomerular filtration rate (GFR) &lt;60 mL/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with Hypoalbuminemia</measure>
    <time_frame>Baseline</time_frame>
    <description>Hypoalbuminemia is considered if Albumin &lt; 34 g/L</description>
  </other_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Bladder Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bone mineral density (BMD)</intervention_name>
    <description>Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males who underwent radical cystectomy with urinary diversion (ileal conduit or neobladder)&#xD;
        after at least one year.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who understand, agree to participate and sign the informed consent.&#xD;
&#xD;
          -  Males older than 50 years old.&#xD;
&#xD;
          -  Patients undergoing radical cystectomy with ileal conduit or neobladder.&#xD;
&#xD;
          -  Time over one year after radical cystectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female gender.&#xD;
&#xD;
          -  Males below 50 years old.&#xD;
&#xD;
          -  Radical cystectomy performed less than one year before.&#xD;
&#xD;
          -  Radical cystectomy with cutaneous ureterostomy.&#xD;
&#xD;
          -  Patients diagnosed with primary hyperparathyroidism, hyperthyroidism or systemic lupus&#xD;
             erythematosus.&#xD;
&#xD;
          -  Patients treated with drugs known to interfere with bone metabolism (including&#xD;
             hormonal treatment, biphosphonates or Denosumab) or previously diagnosed with&#xD;
             osteoporosis.&#xD;
&#xD;
          -  Patients with a history of hemodialysis or renal transplantation.&#xD;
&#xD;
          -  Patients who are under active treatment with chemotherapy or immunotherapy due to&#xD;
             bladder tumor progression or the appearance/progression of a second malignancy.&#xD;
&#xD;
          -  Any patient who does not agree to participate or does not sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Domínguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Parc Taulí</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arturo Domínguez, MD</last_name>
    <phone>+0034 937458407</phone>
    <email>adominguez@tauli.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Domínguez, MD</last_name>
      <phone>+0034 937458407</phone>
      <email>adominguez@tauli.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Arturo Dominguez-Garcia</investigator_full_name>
    <investigator_title>Principal investigator, bladder tumor department coordinator</investigator_title>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Trabecular bone score</keyword>
  <keyword>FRAX</keyword>
  <keyword>Radical cystectomy</keyword>
  <keyword>Fracture risk</keyword>
  <keyword>Metabolic acidosis</keyword>
  <keyword>Vertebral fracture assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

